Literature DB >> 25307543

Collagen type IV-related nephropathies in Portugal: pathogenic COL4A3 and COL4A4 mutations and clinical characterization of 25 families.

M J Nabais Sá1,2, H Storey3, F Flinter4, M Nagel5, S Sampaio2,6, R Castro7, J A Araújo8, M A Gaspar9, C Soares10, A Oliveira11, A C Henriques12, A G da Costa13, C P Abreu14, P Ponce15, R Alves16, L Pinho11, S E Silva17, C P de Moura18,19, L Mendonça20, F Carvalho1, M Pestana2,6, S Alves1, F Carvalho1, J P Oliveira1,2,19.   

Abstract

Pathogenic mutations in genes COL4A3/COL4A4 are responsible for autosomal Alport syndrome (AS) and thin basement membrane nephropathy (TBMN). We used Sanger sequencing to analyze all exons and splice site regions of COL4A3/COL4A4, in 40 unrelated Portuguese probands with clinical suspicion of AS/TBMN. To assess genotype-phenotype correlations, we compared clinically relevant phenotypes/outcomes between homozygous/compound heterozygous and apparently heterozygous patients. Seventeen novel and four reportedly pathogenic COL4A3/COL4A4 mutations were identified in 62.5% (25/40) of the probands. Regardless of the mutated gene, all patients with ARAS manifested chronic renal failure (CRF) and hearing loss, whereas a minority of the apparently heterozygous patients had CRF or extrarenal symptoms. CRF was diagnosed at a significantly younger age in patients with ARAS. In our families, the occurrence of COL4A3/COL4A4 mutations was higher, while the prevalence of XLAS was lower than expected. Overall, a pathogenic COL4A3/COL4A4/COL4A5 mutation was identified in >50% of patients with fewer than three of the standard diagnostic criteria of AS. With such a population background, simultaneous next-generation sequencing of all three genes may be recommended as the most expedite approach to diagnose collagen IV-related glomerular basement membrane nephropathies.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Alport syndrome; COL4A3; COL4A4; COL4A5; thin basement membrane nephropathy

Mesh:

Substances:

Year:  2014        PMID: 25307543     DOI: 10.1111/cge.12521

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  9 in total

1.  COL4A4 variant recently identified: lessons learned in variant interpretation-a case report.

Authors:  Jenelle Cocorpus; Megan M Hager; Corinne Benchimol; Vanesa Bijol; Fadi Salem; Sumit Punj; Laura Castellanos; Pamela Singer; Christine B Sethna; Abby Basalely
Journal:  BMC Nephrol       Date:  2022-07-16       Impact factor: 2.585

2.  Mutation analysis of COL4A3 and COL4A4 genes in a Chinese autosomal-dominant Alport syndrome family.

Authors:  Liwei Guo; Duan Li; Shuangshuang Dong; Donghao Wan; Baosheng Yang; Yanmei Huang
Journal:  J Genet       Date:  2017-06       Impact factor: 1.166

3.  Panel sequencing distinguishes monogenic forms of nephritis from nephrosis in children.

Authors:  David Schapiro; Ankana Daga; Jennifer A Lawson; Amar J Majmundar; Svjetlana Lovric; Weizhen Tan; Jillian K Warejko; Inés Fessi; Jia Rao; Merlin Airik; Heon Yung Gee; Ronen Schneider; Eugen Widmeier; Tobias Hermle; Shazia Ashraf; Tilman Jobst-Schwan; Amelie T van der Ven; Makiko Nakayama; Shirlee Shril; Daniela A Braun; Friedhelm Hildebrandt
Journal:  Nephrol Dial Transplant       Date:  2019-03-01       Impact factor: 5.992

4.  ANCA vasculitis in a patient with Alport syndrome: a difficult diagnosis but a treatable disease!

Authors:  Valentine Gillion; Michel Jadoul; Selda Aydin; Nathalie Godefroid
Journal:  BMC Nephrol       Date:  2017-03-29       Impact factor: 2.388

Review 5.  How to resolve confusion in the clinical setting for the diagnosis of heterozygous COL4A3 or COL4A4 gene variants? Discussion and suggestions from nephrologists.

Authors:  Aya Imafuku; Kandai Nozu; Naoki Sawa; Koichi Nakanishi; Yoshifumi Ubara
Journal:  Clin Exp Nephrol       Date:  2020-03-30       Impact factor: 2.801

6.  Prognostic significance of abnormal matrix collagen remodeling in colorectal cancer based on histologic and bioinformatics analysis.

Authors:  Yuqi Liang; Zhihao Lv; Guohang Huang; Jingchun Qin; Huixuan Li; Feifei Nong; Bin Wen
Journal:  Oncol Rep       Date:  2020-08-11       Impact factor: 3.906

7.  Features of Autosomal Recessive Alport Syndrome: A Systematic Review.

Authors:  Jiwon M Lee; Kandai Nozu; Dae Eun Choi; Hee Gyung Kang; Ii-Soo Ha; Hae Ii Cheong
Journal:  J Clin Med       Date:  2019-02-03       Impact factor: 4.241

8.  Comparison between conventional and comprehensive sequencing approaches for genetic diagnosis of Alport syndrome.

Authors:  Tomohiko Yamamura; Kandai Nozu; Shogo Minamikawa; Tomoko Horinouchi; Nana Sakakibara; China Nagano; Yuya Aoto; Shinya Ishiko; Koichi Nakanishi; Yuko Shima; Hiroaki Nagase; Rini Rossanti; Ming J Ye; Yoshimi Nozu; Shingo Ishimori; Naoya Morisada; Hiroshi Kaito; Kazumoto Iijima
Journal:  Mol Genet Genomic Med       Date:  2019-07-30       Impact factor: 2.183

9.  Improving genetic diagnosis by disease-specific, ACMG/AMP variant interpretation guidelines for hearing loss.

Authors:  So Young Kim; Bong Jik Kim; Doo Yi Oh; Jin Hee Han; Nayoung Yi; Namju Justin Kim; Moo Kyun Park; Changwon Keum; Go Hun Seo; Byung Yoon Choi
Journal:  Sci Rep       Date:  2022-07-21       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.